MA37896A1 - Azahétérocycles utilisés comme inhibiteurs de bir2 et/ou bir3 - Google Patents

Azahétérocycles utilisés comme inhibiteurs de bir2 et/ou bir3

Info

Publication number
MA37896A1
MA37896A1 MA37896A MA37896A MA37896A1 MA 37896 A1 MA37896 A1 MA 37896A1 MA 37896 A MA37896 A MA 37896A MA 37896 A MA37896 A MA 37896A MA 37896 A1 MA37896 A1 MA 37896A1
Authority
MA
Morocco
Prior art keywords
azaheterocycles
bir2
bir3
inhibitors
compounds
Prior art date
Application number
MA37896A
Other languages
English (en)
Inventor
Yan Lou
Joan Heather Hogg
Kang Le
Steven Regory Mischke
Stacy Remiszewski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37896(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37896A1 publication Critical patent/MA37896A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule (i) ou leurs sels de qualité pharmaceutique, dans laquelle r
MA37896A 2012-08-15 2013-08-06 Azahétérocycles utilisés comme inhibiteurs de bir2 et/ou bir3 MA37896A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683253P 2012-08-15 2012-08-15
PCT/EP2013/066458 WO2014026882A1 (fr) 2012-08-15 2013-08-06 Azahétérocycles utilisés comme inhibiteurs de bir2 et/ou bir3

Publications (1)

Publication Number Publication Date
MA37896A1 true MA37896A1 (fr) 2016-09-30

Family

ID=48948413

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37896A MA37896A1 (fr) 2012-08-15 2013-08-06 Azahétérocycles utilisés comme inhibiteurs de bir2 et/ou bir3

Country Status (20)

Country Link
US (1) US9422332B2 (fr)
EP (1) EP2885275A1 (fr)
JP (1) JP6203261B2 (fr)
KR (1) KR20150042792A (fr)
CN (1) CN104540806B (fr)
AU (1) AU2013304214A1 (fr)
BR (1) BR112015003201A2 (fr)
CA (1) CA2878106A1 (fr)
CL (1) CL2015000333A1 (fr)
CO (1) CO7180196A2 (fr)
CR (1) CR20150041A (fr)
EA (1) EA201590347A1 (fr)
IL (1) IL237063A0 (fr)
MA (1) MA37896A1 (fr)
MX (1) MX2015001905A (fr)
PE (1) PE20150674A1 (fr)
PH (1) PH12015500185B1 (fr)
SG (1) SG11201500581WA (fr)
WO (1) WO2014026882A1 (fr)
ZA (1) ZA201500342B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016079527A1 (fr) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Polythérapie
WO2016097773A1 (fr) 2014-12-19 2016-06-23 Children's Cancer Institute Antagonistes des iap thérapeutiques pour traiter des troubles prolifératifs
JP6945546B2 (ja) * 2016-03-22 2021-10-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新規誘導体、及びカスパーゼ−２の選択的阻害剤としての使用
WO2017194390A1 (fr) * 2016-05-09 2017-11-16 F. Hoffmann-La Roche Ag Composés dimères
CN106265764B (zh) 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
TW202500133A (zh) * 2023-03-14 2025-01-01 美商賽堤爾醫療公司 ３﹐４－稠合雙環吡咯啶及３﹐４－稠合雙環吡咯啶酮化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094833A (zh) * 2004-07-12 2007-12-26 伊邓药品公司 四肽类似物
CA2573644A1 (fr) * 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Analogues de tetrapeptide
US8551955B2 (en) * 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics

Also Published As

Publication number Publication date
KR20150042792A (ko) 2015-04-21
CN104540806B (zh) 2017-05-03
PE20150674A1 (es) 2015-05-06
BR112015003201A2 (pt) 2017-07-04
PH12015500185A1 (en) 2015-04-20
HK1209427A1 (en) 2016-04-01
CN104540806A (zh) 2015-04-22
EP2885275A1 (fr) 2015-06-24
JP6203261B2 (ja) 2017-09-27
WO2014026882A1 (fr) 2014-02-20
AU2013304214A1 (en) 2015-02-12
US20150210739A1 (en) 2015-07-30
CL2015000333A1 (es) 2015-11-06
MX2015001905A (es) 2015-06-05
CR20150041A (es) 2015-03-13
PH12015500185B1 (en) 2015-04-20
CA2878106A1 (fr) 2014-02-20
EA201590347A1 (ru) 2015-05-29
IL237063A0 (en) 2015-03-31
SG11201500581WA (en) 2015-04-29
JP2015526436A (ja) 2015-09-10
CO7180196A2 (es) 2015-02-09
ZA201500342B (en) 2017-09-27
US9422332B2 (en) 2016-08-23

Similar Documents

Publication Publication Date Title
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
EA201201663A1 (ru) Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1
MA38050A1 (fr) Inhibiteurs de gdf-8
MA39172A1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
UA110612C2 (uk) Похідні 1-аміно-2-циклопропілетилборонової кислоти
MA33492B1 (fr) Inhibiteurs de bace
EA201290632A1 (ru) Производные бетулина
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA201300211A1 (ru) N-ацилсульфонамидные промоторы апоптоза
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
MX390726B (es) Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen tales compuestos.
IN2014CN04530A (fr)
MA35049B1 (fr) Triazolopyridines
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA37896A1 (fr) Azahétérocycles utilisés comme inhibiteurs de bir2 et/ou bir3
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
PH12013502516A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EA201170997A1 (ru) Производные индола в качестве противораковых агентов